<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971383</url>
  </required_header>
  <id_info>
    <org_study_id>QF-WKP-203</org_study_id>
    <nct_id>NCT03971383</nct_id>
  </id_info>
  <brief_title>Phase Ⅱc Sutdy of Aolanti Weikang Tablets in FD PDS Patients</brief_title>
  <official_title>A Multi-Center, Randomized, Double Blind, Placebo-controlled Phase Ⅱc Study of Aolanti Weipang Tablets in Patients With Postprandial Discomfort Syndrome of Functional Dyspepsia to Evaluate the Safety and Validity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and validity of Aolanti Weipang Tablets
      in Patients with Postprandial Discomfort Syndrome of Functional Dyspepsia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double blind, placebo-controlled phase Ⅱc study to
      evaluate the safety and validity of Aolanti Weipang Tablets in patients with postprandial
      discomfort syndrome of Functional Dyspepsia(FD). This study will consecutive about 12 weeks,
      including 2 weeks of screening, 1 week of blank run-in, 1 week of placebo run-in, 4 weeks of
      double blind treatment and 4 weeks of observation after treatment. The subjects will be
      randomly given orally Aolanti Weikang Tablets or placebo tablets at a 1:1 ratio three times a
      day(tid) with 3 tablets one time for the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2019</start_date>
  <completion_date type="Anticipated">May 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The response rate of patient's on the syndrome of postprandial discomfort</measure>
    <time_frame>4 weeks</time_frame>
    <description>the response rate of patients on the syndrome of postprandial discomfort, patient's evaluation of symptomatic improvement by overall treatment efficacy is classified by 7 point Likert scale: Significantly improved Improved Slightly improved No change Slightly worse Worse Much worse And only the Improved and Significantly improved classified as responsed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The response rate of patient's on the syndrome of postprandial discomfort and early satiation</measure>
    <time_frame>8 weeks</time_frame>
    <description>the response rate of patient's on the syndrome of postprandial discomfort and early satiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The response rate of patient's on the syndrome of early satiation</measure>
    <time_frame>8 weeks</time_frame>
    <description>the response rate of patient's on the syndrome of early satiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety of Aolanti Weikang Tablets on patients</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number and grade of treatment-related adverse events, all of theAE are assessed by NCI-CTCAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Aolanti Weipang Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets one time, 3 times a day(tid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 tablets one time, 3 times a day(tid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aolanti Weipang Tablets</intervention_name>
    <description>3 tablets one time, 3 times a day(tid)</description>
    <arm_group_label>Aolanti Weipang Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 tablets one time, 3 times a day(tid)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with FD according to the ROME Ⅳ criteria，and must with symptom of
             bothersome postprandial fullness;

          -  Patients diagnosed with Stagnation of Qi according to traditional Chinese medicine;

          -  At least the symptom of bothersome postprandial fullness ≥4 on the Visual Analogue
             Scale(VAS), and the number of recurrence day must ≥3 in one week;

          -  Provides voluntary informed consent after receiving adequate explanation and
             demonstrates thorough understanding of the nature of the study.

        Exclusion Criteria:

          -  The patients with high placebo effect, the scores in placebo run-in stage declined
             much than 30 percent of the mean VAS per week compare to blank run-in stage;

          -  Unable to take drugs orally;

          -  Within 7 days of Screening, the average number of stool &gt; 2 times/day;

          -  Within 7 days of Screening, with the presence of ≥ type 5 stool form per the Bristol
             Stool Form Scale;

          -  History of drug or aurantium allergy;

          -  Patients with positive in fecal occult blood test;

          -  Abnormal liver and/or kidney function: creatinine &gt;1.5*ULN (upper limits of normal),
             and/or AST and/or ALT &gt; 2.0*ULN, and/or TBil &gt; 1.5*ULN;

          -  Patients with family history of prolonged QT syndrome or have history of torsional
             apical ventricular tachycardia; or QTc &gt; 480 ms;

          -  Digestive diseases, or other diseases within 6 months before Screening that may affect
             the swallow, absorption, or metabolism of study drugs, and not yet fully recovered
             judged by the Investigator;

          -  Patients who positive in H. Pylori test plan to accept the H. pylori eradication
             therapy within the trial;

          -  Serious complications (heart, brain, lung, liver, kidney, or blood disease);

          -  Neuropsychiatric disorders;

          -  Use of prohibited medications;

          -  Pregnant or lactating women or those who are planning to conceive during the study
             period;

          -  Drug abuse within 3 months, or alcohol abuse within 6 months;

          -  Patients participated in other clinical trials within 30 days before taking drugs;

          -  Other conditions deemed ineligible for enrollment by Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Ke</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second People's Hospital of Fujian Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qinsheng Zhang</last_name>
    <phone>+86-18036618691</phone>
    <email>zhangqinsheng@sh-qingfeng.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lihua Qing</last_name>
    <phone>+86-17717385428</phone>
    <email>qinglihua@sh-qingfeng.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second People's Hospital of Fujian Province</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Yao</last_name>
      <phone>+86-13600803702</phone>
      <email>yjyllbgs@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

